Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Gröbenzell

2 clinical trials in Gröbenzell, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Gröbenzell at a glance
2
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Gröbenzell

Open in trial search

Triple negative breast cancer+4

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:WSG Women's Cancer Study Group GmbH

Breast cancer+2

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Other cities in Germany

The busiest research cities in the country

All 515 cities in Germany

Clinical research in Gröbenzell

What the registry says about research in the country

01 Gröbenzell
Clinical Trial Landscape in Gröbenzell
Gröbenzell currently hosts 2 recruiting clinical trials concentrating on oncology, with two dedicated research sites and investigators actively engaged in advancing cancer care. 2 active trials focused on early breast cancer Collaborative efforts across local institutions Emphasis on neoadjuvant therapeutic strategies Commitment to improving patient outcomes The city’s research environment underscores its role in European oncology innovation.
HER2+ Early Breast Cancer
In Gröbenzell, researchers are conducting a recruiting study focused on HER2+ early breast cancer, assessing a novel neoadjuvant treatment that combines targeted therapy with chemotherapy. The trial aims to compare safety and effectiveness against standard regimens, with particular attention to severe adverse events and long‑term disease control. Safety profiling of innovative antibody‑drug conjugates Evaluation of pathological complete response (pCR) 3‑year distant disease‑free survival analysis Personalized treatment adaptation based on biomarkers The collaborative effort involves two sites and investigators, highlighting Gröbenzell’s growing role in advancing breast cancer therapeutics.
Triple‑Negative Early Breast Cancer (Low‑Risk)
A second recruiting trial in the city examines a triple‑negative early breast cancer cohort with low recurrence risk, testing a combination of sacituzumab govitecan and immunotherapy. The study’s primary goals are to demonstrate superior pathological complete response and to achieve an improved 3‑year invasive disease‑free survival compared with historical outcomes. Combination of antibody‑drug conjugate and checkpoint inhibitor Assessment of pCR rates 3‑year iDFS benchmark exceeding historical control Exploration of biomarker‑guided therapy By integrating cutting‑edge agents, the trial seeks to expand treatment options for patients traditionally lacking targeted therapies, reinforcing Gröbenzell’s commitment to oncology research.
Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.